These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7711418)

  • 1. Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. I. Uric acid kinetics.
    Löffler W; Landthaler R; de Vries JX; Walter-Sack I; Ittensohn A; Voss A; Zöllner N
    Clin Investig; 1994 Dec; 72(12):1071-5. PubMed ID: 7711418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. II. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide.
    de Vries JX; Voss A; Ittensohn A; Walter-Sack I; Löffler W; Landthaler R; Zöllner N
    Clin Investig; 1994 Dec; 72(12):1076-81. PubMed ID: 7711419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.
    Breithaupt B; Tittel M
    Eur J Clin Pharmacol; 1982; 22(1):77-84. PubMed ID: 7094977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a thiazide-allopurinol drug interaction.
    Hande KR
    Am J Med Sci; 1986 Oct; 292(4):213-6. PubMed ID: 3752167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.
    Turnheim K; Krivanek P; Oberbauer R
    Br J Clin Pharmacol; 1999 Oct; 48(4):501-9. PubMed ID: 10583019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.
    Colin JN; Farinotti R; Fredj G; Tod M; Clavel JP; Vignon E; Dietlin F
    Eur J Clin Pharmacol; 1986; 31(1):53-8. PubMed ID: 3780828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained reductions in oxipurinol renal clearance during a restricted diet.
    Park GD; Berlinger WG; Spector R; Kitt TM; Tsalikian E
    Clin Pharmacol Ther; 1987 Jun; 41(6):616-21. PubMed ID: 3581647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals.
    Walter-Sack I; de Vries JX; Kutschker C; Ittensohn A; Voss A
    Eur J Clin Pharmacol; 1995; 49(3):215-20. PubMed ID: 8665998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients - therapeutic equivalence to allopurinol.
    Walter-Sack I; de Vries JX; Ernst B; Frei M; Kolb S; Kosmowski J; Priebe U; Schroder HE; Slotty C; Voss A; Weber A; Wegscheider K
    J Rheumatol; 1996 Mar; 23(3):498-501. PubMed ID: 8832991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers.
    Ng DY; Stocker SL; Graham GG; Williams KM; Day RO
    Eur J Clin Pharmacol; 2011 Jul; 67(7):709-13. PubMed ID: 21181139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of furosemide on renal excretion of oxypurinol and purine bases.
    Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Hada T
    Metabolism; 2001 Feb; 50(2):241-5. PubMed ID: 11229436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A study of serum oxipurinol concentration and renal function in patients administered allopurinol].
    Saji M
    Nihon Jinzo Gakkai Shi; 1996 Dec; 38(12):640-50. PubMed ID: 9014485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol.
    Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Hada T
    J Rheumatol; 2001 Oct; 28(10):2294-7. PubMed ID: 11669172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Uric acid-lowering effect of a combination of benzbromarone and allopurinol--studies under standardized dietary conditions].
    Löffler W; Gröbner W; Zöllner N
    Arzneimittelforschung; 1983; 33(12):1687-91. PubMed ID: 6686776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allopurinol: a comparative study of the bioavailability and effect on plasma uric acid of two products in tablet form.
    Nissen P; Pedersen L
    Biopharm Drug Dispos; 1985; 6(4):441-6. PubMed ID: 4084669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of dose-response relationships of allopurinol in the presence of low or high purine turnover.
    Löffler W; Gröbner W
    Klin Wochenschr; 1988 Feb; 66(4):153-9. PubMed ID: 2453704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Difference of the plasma concentration and urinary excretion of allopurinol, oxypurinol, and purine bases between dietary intake and fasting.
    Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Yamakita J; Higashino K
    Int J Clin Pharmacol Ther; 1996 Apr; 34(4):157-62. PubMed ID: 8861734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of benzbromarone and its combination with hydrochlorothiazide on renal excretion of uric acid and electrolytes.
    Malý J; Schück O
    Int J Clin Pharmacol Ther Toxicol; 1990 Oct; 28(10):443-5. PubMed ID: 2258255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of angiotensin II infusion on renal excretion of purine bases and oxypurinol.
    Moriwaki Y; Yamamoto T; Tsutsumi Z; Takahashi S; Hada T
    Metabolism; 2002 Jul; 51(7):893-5. PubMed ID: 12077737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.
    Day RO; Miners JO; Birkett DJ; Whitehead A; Naidoo D; Hayes J; Savdie E
    Br J Clin Pharmacol; 1988 Oct; 26(4):423-8. PubMed ID: 3190992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.